Genzyme, a Sanofi company (NYSE: SNY), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), announced today that the US FDA Approved KYNAMRO (mipomersen sodium) for the treatment of patients with Homozygous Familial Hypercholesterolemia (HoFH). Many people with HoFH have aggressive cardiovascular disease beginning in childhood, and even with today’s therapies remain at significant risk of cardiovascular events Kynamro is quite unique. It's based on antisense technology, which is a newer field that could have interesting medical applications in coming years. ISIS pharmaceuticals itself is basing its pipeline on this new technology and its implications. In addition to Kynamro, the company is exploring antisense inhibitors for target proteins CRP, ApoCIII, and Factor XI as well.
Kynamro's approval could mean quite a lot to ISIS investors, despite the fact that it was licensed to Genzyme Corporation. Although Genzyme has already paid $175 million for Kynamro through licensing fees, ISIS stands to generate additional milestone payment revenue from the drug after its potential approval, and might have other partnering opportunities due to Genzyme's equity in ISIS.
.. the approval of Isis Pharma Sanofi's candidate